VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure May 4, 2024 — 18:00
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers May 2, 2024 — 07:01
Chinese new energy industry contributes to global green, low-carbon transition April 30, 2024 — 15:13
Every Dollar Lost to Fraud in Australia Costs Firms AUD$3.68 According to LexisNexis True Cost of Fraud Study April 29, 2024 — 07:00
PR Newswire
